Analysis of pharmacodynamic markers within harvested PTEN-deficient tumour samples similarly indicated IR to induce the expression of Bcl-2, a known mediator of RT resistance in a number of cancer models, but that this was attenuated by inhibition of CXCR1/CXCR2 signalling (35). The gene discussed is BCL2; the disease is cancer.